Evonik, OPX Biotechnologies to jointly develop bio-based chemicals
Evonik Industries and OPX Biotechnologies (OPXBIO) have signed an agreement to jointly develop certain bio-based specialty chemicals.
The joint-development agreement, which was signed on 3 May 2013, necessitates OPXBIO to employ its patented Efficiency Directed Genome Engineering (EDGE) technology to develop the bio-processes.
Creavis Science-to-Business Center Biotechnology vice president Dr. Thomas Haas said: "There's a growing market demand for more sustainable products and processes, and OPXBIO is an excellent partner to help us meet that demand because their technology can create high-value, bio-based chemicals quickly and cost-effectively."
The agreement will also enable OPXBIO to market bio-based products resulting from the Evonik partnership.
OPX Biotechnologies president and CEO Charles Eggert said: "The bio-process we're developing has the potential to create economic and sustainable versions of products we use in our everyday lives."
Creavis is the strategic research and development unit of Evonik.